Gibson Dunn (Washington)

Stephen Weissman

Gibson Dunn (Washington)
Lawyer (Partner)

Stephen Weissman is a partner in Gibson Dunn’ Washington, D.C. office. He recently rejoined the firm after serving as the Deputy Director of the Federal Trade Commission’s Bureau of Competition from 2013 to 2015. At the FTC he was involved in and supervised the agency’s review of hundreds of merger and non-merger investigations and enforcement actions, covering a wide range of industries including pharmaceuticals and other healthcare sectors, consumer products, energy, high-tech and general manufacturing. In almost two decades of private practice, he has represented companies and individuals in antitrust investigations by the Department of Justice and Federal Trade Commission, as well as in antitrust and commercial litigation in U.S. courts. He represents both acquiring and acquired companies as well as third parties in merger investigations. He also regularly counsels clients in criminal antitrust investigations and on issues pertaining to joint ventures and distribution arrangements. Stephen Weissman holds a J.D. degree from the University of Pennsylvania Law School.

Linked authors

King’s College (London)
Gibson Dunn (Brussels)
Gibson Dunn (San Francisco)
Gibson Dunn (New York)
Gibson Dunn (Dubai)


230 Bulletin

Stephen Weissman, Catriona Hatton, John M. Taladay The US District Court of Delaware spotlights the importance of antitrust risk-shifting provisions in merger agreements in the pharmaceutical sector (Akorn / Fresenius)


As counsel involved in negotiating mergers, acquisitions, or other transactions know, provisions that allocate antitrust risk between buyer and seller, or between joint venture (JV) partners, are a common feature of merger and JV agreements. Such provisions are increasingly important in today’s (...)

Nathan Chubb, Catriona Hatton, Michael J. Perry, Stephen Weissman The US Government Accountability Office publishes the results of its study into the prescription drug industry


Prior to the year-end holiday season, the United States Government Accountability Office (“GAO”) released the results of its long-awaited study into the prescription drug industry’s “Profits, Research and Development Spending, and Merger and Acquisition Deals.” The report responds to Congressional (...)

Nathan Chubb, John M. Taladay, Stephen Weissman, Joseph Ostoyich The US Court of Appeals for the Third Circuit rejects antitrust claims predicated on a supplier’s market-share discount program and other promotional tactics (Eisai / Sanofi)


On May 4, 2016, the U.S. Court of Appeals for the Third Circuit announced its decision in Eisai, Inc. v. Sanofi Aventis U.S., LLC, rejecting antitrust claims predicated on a supplier’s market-share discount program and other promotional tactics. While the court’s decision adds some definition to (...)

Send a message